A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cardiology"
DOI: 10.1002/clc.22687
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates low‐density lipoprotein (LDL) receptors, thereby leading to a rise in circulating LDL cholesterol (LDL‐C). RG7652 is a fully human monoclonal antibody against PCSK9. This placebo‐controlled, phase 1 ascending‐dose… read more here.
Keywords: ldl cholesterol; proprotein convertase; ldl; subtilisin kexin ... See more keywords
Emerging role of proprotein convertase subtilisin/kexin type‐9 (PCSK‐9) in inflammation and diseases
Sign Up to like & getrecommendations! Published in 2019 at "Toxicology and Applied Pharmacology"
DOI: 10.1016/j.taap.2019.03.018
Abstract: ABSTRACT Proprotein convertase subtilisin/kexin type‐9 (PCSK9) is most recognized serine protease for its role in cardiovascular diseases (CVD). PCSK9 regulates plasma low‐density lipoprotein cholesterol (LDL‐C) levels by selectively targeting hepatic LDL receptors (LDLR) for degradation,… read more here.
Keywords: proprotein convertase; subtilisin kexin; pcsk9; role ... See more keywords
PERSISTENCE AND ADHERENCE WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS IN CLINICAL PRACTICE
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)33548-9
Abstract: Background: Elevated low-density lipoprotein cholesterol (LDL-C) is associated with premature atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have shown reductions in LDL-C levels in patients uncontrolled by statin and/or ezetimibe therapy. read more here.
Keywords: proprotein convertase; subtilisin kexin; kexin type; type inhibitors ... See more keywords
ASSOCIATIONS BETWEEN CIRCULATING LEVELS OF PLASMA OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 AND VASCULAR OUTCOMES IN AFRICAN AMERICAN DIABETIC PATIENTS
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)32365-9
Abstract: Studies showed conflicting results for the association of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) with glycemic parameters and risk of type 2 diabetes. Whether plasma levels of PCSK9 could directly influence vascular function is… read more here.
Keywords: proprotein convertase; subtilisin kexin; kexin type; type ... See more keywords
LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(19)32320-4
Abstract: LIB003 is a 77 kDa recombinant fusion protein consisting of an adnectin, derived from the 10th type III domain of human fibronectin and targeted with high affinity to proprotein convertase subtilisin/kexin type 9 (PCSK9), and… read more here.
Keywords: fusion protein; subtilisin kexin; kexin type; convertase subtilisin ... See more keywords
ACUTE KIDNEY INJURY: A RARE CONSEQUENCE OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR USE
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)33011-4
Abstract: Acute kidney injury (AKI) is not a reported side effect of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK-9) inhibitor therapy. PCSK-9 inhibitors are cleared via the reticuloendothelial system and are considered nontoxic to the kidney. A… read more here.
Keywords: kidney injury; proprotein convertase; acute kidney; subtilisin kexin ... See more keywords
Chemical Constituents from the Roots and Rhizomes of Sophora tonkinensis and Their Effects on Proprotein Convertase Substilisin/Kexin Type 9 Expression
Sign Up to like & getrecommendations! Published in 2022 at "ACS Omega"
DOI: 10.1021/acsomega.2c01676
Abstract: This study was conducted to further investigate bioactive molecules from Sophora tonkinensis that can inhibit proprotein convertase substilisin/kexin type 9 (PCSK9) expression. After interpreting NMR spectroscopic data and MS spectral data of all isolates, a… read more here.
Keywords: convertase substilisin; substilisin kexin; expression; proprotein convertase ... See more keywords
Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats
Sign Up to like & getrecommendations! Published in 2020 at "Acta Pharmacologica Sinica"
DOI: 10.1038/s41401-020-0392-8
Abstract: Hyperlipidemia (HPL) characterized by metabolic disorder of lipids and cholesterol is one of the important risk factors for cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a potent circulating regulator of LDL through its… read more here.
Keywords: proprotein convertase; cholesterol; hpl; subtilisin kexin ... See more keywords
Relation Between Proprotein Convertase Subtilisin/Kexin Type 9 and Directly Measured Low-Density Lipoprotein Cholesterol
Sign Up to like & getrecommendations! Published in 2017 at "Baylor University Medical Center Proceedings"
DOI: 10.1080/08998280.2017.11929514
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of low-density lipoprotein cholesterol (LDL-C) receptor (LDL-R) recycling and, thus, is a determinant of plasma LDL-C concentration. We sought to determine the relation between serum concentrations… read more here.
Keywords: proprotein convertase; cholesterol; subtilisin kexin; pcsk9 ... See more keywords
Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Enzyme Inhibition and Medicinal Chemistry"
DOI: 10.1080/14756366.2022.2101645
Abstract: Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs. In the discovery of PCSK9/LDLR (low-density lipoprotein receptor) protein-protein interaction (PPI) impairing small molecules, a… read more here.
Keywords: phenylbenzo dioxole; dioxole based; subtilisin kexin; proprotein convertase ... See more keywords
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Sign Up to like & getrecommendations! Published in 2018 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehy122
Abstract: Aims Lipoprotein(a) [Lp(a)], a low-density lipoprotein (LDL) particle covalently bound to apolipoprotein(a) [apo(a)], is a potentially potent heritable risk factor for cardiovascular disease. We investigated the mechanism whereby evolocumab, a monoclonal antibody against proprotein convertase… read more here.
Keywords: proprotein convertase; effect; subtilisin kexin; particle ... See more keywords